C2N Diagnostics is set to relocate and expand its headquarters in St. Louis, tripling its operational footprint to meet the growing global demand for Alzheimer’s disease diagnostics. The company will move into 82,451 square feet at Catalyst, Powered by WashU, in the Cortex Innovation District, occupying the first three floors of the redeveloped former Goodwill Industries International site. The new facility will feature a federally regulated, CAP-accredited, and CLIA-certified laboratory, incorporating advancements in bioautomation and high-throughput proteomic testing. The relocation is scheduled for completion in late 2026.
In addition to the new headquarters, C2N will maintain its existing ISO 13485:2016-compliant laboratory facility, repurposing it into a center dedicated to providing cutting-edge multi-omic solutions and advanced analytical platforms. This expansion aims to drive innovation across the company’s biopharmaceutical research services, medtech business units, and international collaborative research initiatives.
C2N is recognized for its development of the PrecivityAD® and PrecivityAD2™ blood tests, which assist healthcare professionals in detecting amyloid plaques in the brain—a hallmark of Alzheimer’s disease. These tests aid in medical management and treatment decisions for patients with cognitive impairment. The company’s expansion reflects its commitment to advancing Alzheimer’s disease diagnostics and contributing to the broader field of neurodegenerative research.
